Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease

Article Gastroenterology & Hepatology

Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction

Elisa Proietti et al.

Summary: This study is the first to demonstrate a correlation between serum and tissue UST levels. The tissue IL-23-to-UST ratio correlated with mucosal inflammation, and UST serum levels were more indicative of biochemical response.

INFLAMMATORY BOWEL DISEASES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium

Amanda M. Johnson et al.

Summary: This study evaluated the real-world effectiveness and safety of ustekinumab in patients with Crohn's disease. The results demonstrated that ustekinumab is a safe and effective treatment option for Crohn's disease, especially for biologic-naive patients.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Rates, predictive factors and effectiveness of ustekinumab intensification to 4-or 6-weekly intervals in Crohn's disease

Lauranne A. . A. . P. Derikx et al.

Summary: This study assessed the efficacy of ustekinumab (UST) dose intensification in Crohn's disease (CD) and found that dose intensification from 12- to 8-weekly was effective, but not from 12- to 4-weekly. Factors associated with dose intensification included prior exposure to both anti-TNF and vedolizumab, and concomitant steroid use at UST start. After dose intensification, 62.6% of patients remained on UST beyond 1 year.

DIGESTIVE AND LIVER DISEASE (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases

Hongsheng Yang et al.

Summary: Ustekinumab is effective in treating CD and UC, with a risk of LOR and dose escalation of 21% and 25% respectively in CD patients. After dose escalation, 58% of patients regain clinical response. Limited data is available for LOR in UC patients, but dose escalation has shown a risk of 18% and a remission rate of 58%.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis

Joseph Meserve et al.

Summary: Ustekinumab dose escalation was effective in achieving response in patients with active CD who had inadequate response or loss of response to standard dose induction and/or maintenance therapy.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial

William J. Sandborn et al.

Summary: The IM-UNITI study and long-term extension (LTE) showed that subcutaneous ustekinumab maintenance therapy had long-term efficacy and safety in patients with Crohn's disease, with significant clinical remission rates observed at 5 years. No new safety signals were found.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

Fernando Bermejo et al.

Summary: Intravenous re-induction with ustekinumab is an effective and safe strategy that recovers the response in approximately half of the patients with refractory Crohn's disease who experience a loss of response. Re-induction can be attempted before switching out of the therapy class.

INFLAMMATORY BOWEL DISEASES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China

Qian Cao et al.

Summary: Research shows that ustekinumab is more effective in treating Crohn's disease than anti-tumor necrosis factor treatment for patients who did not respond to previous treatment. The remission rates of ustekinumab are superior to those in the UNITI-1 study.

INFLAMMATORY BOWEL DISEASES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis

Dahham Alsoud et al.

Summary: UST treatment can achieve histological remission in refractory UC patients. There is a strong correlation between serum UST concentrations and tissue drug exposure, indicating limited value in measuring tissue exposure.

JOURNAL OF CROHNS & COLITIS (2022)

添加到收藏夹

Article

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response

Valerie Heron et al.

Journal of the Canadian Association of Gastroenterology (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease

Omoniyi J. Adedokun et al.

Summary: This study evaluated the pharmacokinetics and dose-response relationship of ustekinumab in patients with Crohn's disease. The results showed that the metabolism of ustekinumab in patients is influenced by multiple factors, but these effects do not have clinical significance on ustekinumab exposure. In addition, a positive correlation was established between ustekinumab concentration and efficacy outcomes.

CLINICAL THERAPEUTICS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety and effectiveness of ustekinumab in elderly Crohn's disease patients

Joseph Fiske et al.

Summary: Ustekinumab is a safe and effective treatment for elderly Crohn's disease patients, with a low risk of infections. The risk of serious infections is comparable to that of anti-TNF agents, while steroid exposure increases the risk of infections.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Biologics: how far can they go in Crohn's disease?

Katie A. Dunleavy et al.

Summary: This article summarizes and synthesizes current FDA-approved biological therapy for Crohn's disease and examines the positioning of medical therapy as emerging biologics break onto the market.

GASTROENTEROLOGY REPORT (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study

Jia-yin Yao et al.

Summary: UST is a promising treatment option for refractory Crohn's disease, with an optimal trough concentration above 1.12 μg/mL associated with endoscopic remission at week 16/20 after initiation. Therapeutic monitoring based on drug concentration is crucial for maintaining treatment efficacy in patients.

BMC GASTROENTEROLOGY (2021)

添加到收藏夹

Letter Gastroenterology & Hepatology

Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All

Rahul S. Dalal et al.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing)

JOURNAL OF DIGESTIVE DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease

Sebastiaan ten Bokkel Huinink et al.

Summary: Re-induction with intravenous ustekinumab after secondary loss of response in Crohn's disease leads to continuation of ustekinumab treatment in most patients for at least 1 year and achieves clinical remission in half of the patients after 1 year.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology